Ruti Aga's Six-Year Ban: The Punishment Came From a Prescription Pad That Never Existed

The doctor named on the prescription was never at that clinic. There was no clinic to be at. The "old prescription pad" that was cited has been disowned by the hospital that supposedly issued it. That sequence — laid out in the Athletics Integrity Unit's statement released on Thursday — is the actual story: Ruti Aga, the 32-year-old Ethiopian marathoner, has been banned for six years, and two-thirds of that sanction rests not on what entered her body but on what she handed to investigators. I have spent seventeen years watching the part of the results sheet nobody publishes: who stood on the start line, who came off it, and whose name had no annotation written beside it. This time the name that came off was at the top of the page.

Start with the record, because the ban reads differently without it. Aga won the 2026 Tokyo Marathon — a race I followed from a results desk where the split feed was lagging and the commentary had already called the finish. She has three runner-up finishes at World Marathon Majors. Her personal best sits in the 2:18 to 2:20 range, which places her not among the fastest women in the world but immediately beneath them, in the tier where Major prize money and Asian label-race appearance fees are earned.

In March she won a half marathon in China. The in-competition sample from that race came back positive for methylprednisolone. She had been provisionally suspended from 10 September; the six-year ban is now backdated to the same date. The statement specifies neither the year of the March race, nor her finishing time, nor the strength of the field. What it does say is that she won, and that the sample taken afterwards was positive. Her explanation was a knee injury. Put the two halves together — a runner who has won a Major, and a prescription written by someone with no medical registration — and the distance between them is the whole case.

Correct one thing first, because much of the reporting got it wrong. Methylprednisolone is not an anabolic steroid. It is a glucocorticoid, class S9 on the WADA Prohibited List, while anabolic steroids sit in class S1. That distinction is not about the punishment; it is about the defence: S9 glucocorticoids are prohibited in-competition only, and only by injection, oral or rectal route. A therapeutic knee injection given out of competition is entirely legal. It becomes a violation only if residues are still present on race day.

There is a technical detail here that explains the whole matter. A road race's testing window opens at 23:59 the day before the race. So a runner who had an injection three or four days earlier, with records to prove it, had an argument — timing, route and medical necessity could all have been litigated. Aga had that door open. She closed it with a prescription pad.

Now the arithmetic. Two years for presence, four years for tampering. Six in total. The sum matches standard Code sanctions and tells us the panel weighed two things separately: the substance was proven, but without any proven intent to cheat; and the fabrication of documents was treated as fully culpable conduct. The no-significant-fault reduction did not apply to the two-year presence sanction, because an athlete who manufactures a prescription rather than telling the truth closes that door herself.

Three separate verifications failed on the prescription. One, the clinic did not exist. Two, the person who wrote it was a family member with no medical registration. Three, the "old pad" he claimed was disowned by the hospital he named. Three independent checks, all failed — this is not the shape of an error; it is the shape of a structure with nobody in it whose job was to check.

That is where my real concern begins. On the results crew in Manchester I learned that accuracy is a form of care — one official's miscount can misremember an athlete's career permanently. Read this case the same way: the largest thing missing here is not a doping control, it is a credentialed team doctor. A professional whose note survives verification, who understands the TUE paperwork, who can count the days between an injection and a race. In that place we found a family member who wanted to help and had an old pad. I see less corruption here than absence.

That absence has an economic cause, and it sits off the track. In Ethiopian road running the real currency is not a contract or a transfer. It is an appearance fee, an agent, a bed at camp, a physiotherapist's hour, and whose account the medical bill lands on. For a 32-year-old marathoner with a chronically sore knee, the cheapest route is an injection and the most expensive is paperwork. I am not arguing that this changes the rule. I am saying that on the day an athlete has nobody to file the paperwork on her behalf, the next link in the rule lands on her neck.

The career arithmetic is blunt. Age 32, a six-year ban, a return at roughly 38. Ethiopia's women's marathon depth is such that a 2:18 performer is not automatically selectable. At elite level this is functionally a lifetime ban, whatever the paperwork says. And note what survives: the violation attaches to a later March race, so the 2026 Tokyo title and the three Major runner-up finishes are not automatically annulled. The AIU statement does not specify the disqualification scope; standard practice voids the result and prize money from the race where the sample was collected. She remains, in the record book, the winner of Tokyo 2026 — and in the same record book's margin, a woman removed for six years.

Six years sounds like rigour. The arithmetic says otherwise: two for the drug, four for the document. For a substance with no proven endurance benefit, the sanction has run longer than many of the blood-doping cases we routinely call serious. That number will be used from both directions — as evidence of AIU vigilance, and as evidence of disproportionate enforcement against African road runners. The length of the ban was decided by document verification, not pharmacology. The enforcement frontier has moved from detection to paperwork, and athletes have not been prepared for the shift.

I also owe the boring explanation a hearing, because not every missing name is an injustice. It is possible the knee genuinely needed treating, the injection was genuinely given, and the person who produced the prescription panicked and fabricated a document to protect her. That possibility does not reduce the sanction, because what was submitted was submitted in her name. It does change where we look: the question is not whether she was honest, it is why nobody stood beside her whose signature would survive a check. And that is my second objection — China's label races are now simultaneously the appearance-fee market and the AIU's highest-yield testing ground. Where the money is dense and the field is East African, the testing will be dense too. Calling that strictness is easy. Understanding that cost and scrutiny now share the same race is more useful.

I keep one rule that has held for nine years: no piece without a number I calculated myself, and no number without a name attached to it. The number here is six, and the name is Ruti Aga — but the question behind the number is not what she took. It is who will be standing in the camp next time a 32-year-old's knee gives out, able to write the right document, the right date and the right signature. Until that question has an answer, the next prescription will also belong to a family member — and so will the next six-year ban.